About abrocitinib
Oral Janus kinase 1 inhibitor
Used for
- Treats moderate-to-severe atopic dermatitis (eczema) in adults and adolescents when other systemic treatments are unsuitable or insufficient.
Usual adult dose
Usually 100 mg once daily; may increase to 200 mg once daily if needed and appropriate.
Usual dose in children
Adolescents aged 12 years and older: usually 100 mg once daily; may increase to 200 mg once daily if needed and appropriate.
Common side effects
- Nausea
- Headache
- Acne
- Increased risk of infections, including shingles
Important warnings
- Serious infections can occur; tuberculosis screening is needed before treatment.
- May increase risks of blood clots, major cardiovascular events, and certain cancers.
- Blood counts and cholesterol may need monitoring.
- Avoid live vaccines during treatment.
Pregnancy
Avoid during pregnancy; reliable contraception is advised during treatment and for one month afterward.
Breastfeeding
Breastfeeding is not recommended during treatment or for one day after the last dose.
Interactions
- Strong CYP2C19 inhibitors or CYP2C19/CYP2C9 inducers can change abrocitinib levels.
- Avoid combining with other JAK inhibitors, biologic immunomodulators, or potent immunosuppressants.
- Avoid live vaccines during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.